Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sincalide

FDA-approved product (powder, intravenous), marketed as Kinevac, Sincalide.

Registered studies
10
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Sincalide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Sincalide. Its therapeutic class is shown instead.

WHO therapeutic group
Tests for bile duct patency
FDA pharmacologic class
Cholecystokinin Analog FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

10registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sincalide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sincalide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Mechanisms and Targeted Therapy of Airway Basal Cell Dysfunction in Bronchiolitis Obliterans Syndrome

    NCT07018804 · start 2026-07-26

    Registered record
    Registry ID
    NCT07018804
    Conditions
    Bronchiolitis Obliterans Syndrome (BOS)
    Interventions
    Bronchoscopic brushing; Single - cell cloning; Cell function identification; Identification of local microenvironmental changes; Gene editing; Prevention of ferret airway basal cell transplantation; Transplantation treatment of ferret airway basal cells
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2026-07-26
    Completion
    2028-06-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchiolitis Obliterans Syndrome (BOS)
    InterventionBronchoscopic brushing; Single - cell cloning; Cell function identification; Identification of local microenvironmental changes +3 more
    PhaseNot applicable
    Registry statusWithdrawn

  • POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS

    NCT07019519 · start 2025-03-15

    Registered record
    Registry ID
    NCT07019519
    Conditions
    Postural Orthostatic Tachycardia Syndrome (POTS); Healthy
    Interventions
    Saline/Placebo; GIPR antagonist; GLP-1R antagonist; CCK agonist
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-03-15
    Completion
    2026-09-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostural Orthostatic Tachycardia Syndrome (POTS); Healthy
    InterventionSaline/Placebo; GIPR antagonist; GLP-1R antagonist; CCK agonist
    PhaseNot applicable
    Registry statusRecruiting

  • Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants

    NCT04567667 · start 2020-10-15

    Registered record
    Registry ID
    NCT04567667
    Conditions
    Healthy Volunteers
    Interventions
    [14C] BMS-986278; Kinevac®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-10-15
    Completion
    2021-04-11
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    Intervention[14C] BMS-986278; Kinevac®
    PhasePhase 1
    Registry statusCompleted

  • A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects

    NCT02496221 · start 2015-06-11

    Registered record
    Registry ID
    NCT02496221
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Albiglutide 50 mg; Placebo; CCK (Kinevac)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-06-11
    Completion
    2015-10-13
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionAlbiglutide 50 mg; Placebo; CCK (Kinevac)
    PhasePhase 4
    Registry statusCompleted

  • Impact of Two Genetic Variants of OATP1B3 or MRP2 or Rifampin on Systemic Disposition and Biological Efficacy of CCK-8

    NCT02507167 · start 2012-11

    Registered record
    Registry ID
    NCT02507167
    Conditions
    Gastrointestinal Hormones
    Interventions
    mixed meal; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-12
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Hormones
    Interventionmixed meal; Rifampin
    PhasePhase 1
    Registry statusCompleted

  • The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion

    NCT01656057 · start 2012-07

    Registered record
    Registry ID
    NCT01656057
    Conditions
    To Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion
    Interventions
    Acetaminophen; Metformin; Colesevelam; Cholecystokinin-8; Saline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-07
    Completion
    2014-04
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTo Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion
    InterventionAcetaminophen; Metformin; Colesevelam; Cholecystokinin-8 +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)

    NCT00706381 · start 2008-06-23

    Registered record
    Registry ID
    NCT00706381
    Conditions
    Healthy Volunteers
    Interventions
    Sincalide; Ursodiol; Fat Meal; Carb meal; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-06-23
    Completion
    2012-08-21
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionSincalide; Ursodiol; Fat Meal; Carb meal +1 more
    PhasePhase 3
    Registry statusCompleted

  • Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying

    NCT00685477 · start 2008-05

    Registered record
    Registry ID
    NCT00685477
    Conditions
    Healthy
    Interventions
    Experimental Sequence ABC; Experimental Sequence ACB; Experimental Sequence BAC; Experimental Sequence BCA; Experimental Sequence CAB; Experimental Sequence CBA
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-05
    Completion
    2009-07
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionExperimental Sequence ABC; Experimental Sequence ACB; Experimental Sequence BAC; Experimental Sequence BCA +2 more
    PhaseNot applicable
    Registry statusCompleted

  • Ultrasound for Diagnosis of Biliary Dyskinesia

    NCT00737295 · start 2008-05

    Registered record
    Registry ID
    NCT00737295
    Conditions
    Biliary Dyskinesia
    Interventions
    CCK Injection and Ultrasound
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2008-05
    Completion
    2010-06
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiliary Dyskinesia
    InterventionCCK Injection and Ultrasound
    PhaseNot applicable
    Registry statusTerminated

  • Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis

    NCT00004414 · start 1997-09

    Registered record
    Registry ID
    NCT00004414
    Conditions
    Cholestasis
    Interventions
    sincalide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1997-09
    Completion
    2002-06
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholestasis
    Interventionsincalide
    PhaseNot applicable
    Registry statusCompleted